Venetoclax (Venclexta, Venclyxto)

Medicine at a glance

Venetoclax is a targeted cancer medicine taken as tablets once daily with a meal and water. Verified brands include Venclexta and Venclyxto. It blocks a survival protein called BCL-2. Treatment often includes other medicines, but your venetoclax dose and calendar need their own clear instructions.

Starting safely requires a low dose that increases in planned steps, preventive medicines, a drinking plan and carefully timed blood tests. The starting schedule for chronic lymphocytic leukaemia, or CLL, is different from that for acute myeloid leukaemia, or AML. A hospital stay may be necessary. Never copy another person's schedule or increase your dose without the team's confirmation.

What venetoclax is and how it works

Cells have a controlled process for dying when they are damaged or no longer needed. BCL-2 can help cancer cells resist that process. Venetoclax blocks BCL-2, allowing susceptible cells to die. This is different from traditional chemotherapy, although the medicines may be used together. Targeted treatment can still affect healthy cells and cause serious side effects.

Sometimes venetoclax destroys many cancer cells quickly. The contents released into the blood can overwhelm the kidneys and disturb important mineral levels. This is called tumour lysis syndrome, or TLS. The gradual starting schedule and extra monitoring are central parts of treatment, not optional precautions.

How the team decides whether it is suitable

Your haematologist considers your exact diagnosis, previous treatment, blood and bone-marrow findings, other illnesses, kidney and liver function and all medicines you take. Cancer-cell genetic results may help guide the overall treatment choice. There is not one universal BCL-2 blood-test result that everyone must have before receiving venetoclax.

The team also considers how much disease is present, including enlarged lymph nodes, blood-cell counts and sometimes spleen size. These findings influence TLS risk and whether treatment can start as an outpatient. Reduced kidney function can mean closer monitoring even when it does not require a routine reduction in the venetoclax dose. Severe liver impairment does require dose adjustment.

The accompanying treatment and intended treatment length must be agreed separately. New combination options do not have identical instructions in every region. The benefits, practical demands and alternatives should be discussed in the context of your own care plan.

Before treatment starts

Give the team a complete medicines list, including tablets from other doctors, recent antibiotics, antifungal medicines, supplements and herbal products. Some interactions are especially dangerous during the first dose increases. Tell them about previous infections, hepatitis, difficulty swallowing, pregnancy plans and any heart or kidney condition that limits how much you can drink.

Blood tests check blood-cell counts, kidney and liver function, uric acid and minerals including potassium, phosphate and calcium. Abnormal results may need correction first. Imaging may be used to assess lymph nodes. With AML, the white-cell count should be below 25 × 10⁹/L before starting; separate treatment may be needed to lower it.

You will usually receive medicine to control uric acid, such as allopurinol. For CLL, this generally starts two to three days before venetoclax. Some people need a different medicine, intravenous fluids or admission to hospital. Ask for a written plan showing the tablet dose, preventive medicines, fluid target, blood-test appointments and who confirms the next dose.

Keep the team's daytime and out-of-hours numbers accessible. Arrange transport and practical support for starting days: an apparently routine tablet appointment may involve several blood samples over many hours.

How to take venetoclax

Dose increases and treatment calendars

Take the prescribed dose once a day, at approximately the same time, with a meal and water. Tablets come in 10 mg, 50 mg and 100 mg strengths. Check the strength and total daily dose whenever a new supply arrives. Confirm the number of tablets as well as the total milligrams.

For CLL, the usual starting sequence is 20 mg daily in week one, then 50 mg, 100 mg, 200 mg and finally 400 mg daily, with each step lasting a week. This five-week increase is called a ramp-up. Other medicines or side effects can change the schedule. Starting a partner medicine earlier does not mean venetoclax should also start earlier.

For AML with azacitidine or decitabine, the usual starting sequence is 100 mg on day one, 200 mg on day two and 400 mg daily from day three. A US regimen with low-dose cytarabine uses a different final dose. Interacting medicines can require much smaller doses from the beginning. These examples explain the differences; your prescription determines your actual dose.

Later AML cycles may include fewer venetoclax days because of blood-count recovery, particularly after remission. A shorter course within a cycle is not the same as taking a smaller tablet dose every day. Ask for a fresh calendar after any change.

Drinking and blood-test days

The usual CLL oral-fluid target is 1.5–2 litres a day, starting two days before the first dose and continuing daily through the ramp-up, with particular attention before each increase. People with heart or kidney problems need an individual target: do not force large volumes against a fluid restriction. Intravenous fluids may be needed. AML also requires a planned hydration and uric-acid prevention programme.

On monitored starting days, take the tablets at the time the hospital tells you. Do not take a morning dose early simply to fit your normal routine; blood samples must relate to the actual dosing time.

Swallowing: a recent regional difference

Usually, swallow the tablets whole without chewing or breaking them. If this is difficult, contact the pharmacist before changing how you take them. The May 2026 US Venclexta instructions allow tablets to be crushed for patients unable to swallow them whole. The entire prescribed dose is mixed with 120 mL of water, apple juice, apple sauce or yoghurt and taken immediately, with a meal and water. Only one dose should be prepared at a time. Smaller-strength tablets may be another option.

The current European Venclyxto instructions still say not to chew, crush or break the tablets. These instructions should not be blended: your pharmacist must confirm which method applies to your actual product. The US crushing instructions are not a general feeding-tube protocol. Do not put the medicine down a tube without specialist advice. Crushed tablets can stain skin; the US instructions advise considering disposable gloves when handling them.

Missed doses, vomiting and storage

If you remember less than eight hours after the usual time, take the dose and return to your normal schedule. If more than eight hours have passed, skip it and take the next dose at the usual time the following day. If the timing is exactly at the boundary or you are undergoing monitored dose increases, ask the team. Do not double a dose.

If you vomit after taking venetoclax, do not take another dose that day. Take the next prescribed dose at its usual time, unless the team advises a hold. Repeated vomiting needs prompt advice because dehydration increases risk. Report an accidental extra dose immediately.

Keep tablets in their original packaging as directed on the supplied label, away from children and pets. Ask the pharmacy before transferring a ramp-up pack into an organiser. Return unused medicine to the pharmacy; do not share it or flush it away.

Monitoring and checking whether treatment is working

TLS monitoring is especially intensive at the start. In CLL, many patients have tests before the first 20 mg and 50 mg doses, again six to eight hours afterwards, and at 24 hours. Higher-risk patients may be admitted and tested at four, eight, 12 and 24 hours. Later increases can also need extra samples. Your plan depends on kidney function, disease burden and previous results.

For AML, the standard plan includes blood chemistry before treatment, six to eight hours after each new ramp-up dose and 24 hours after the final ramp-up dose. Some people need more monitoring. Do not assume that feeling well means your blood chemistry is safe. The team may need to review results before the next dose.

Blood counts continue throughout treatment to detect low infection-fighting cells, anaemia and low platelets. Kidney, liver and other blood tests are repeated as appropriate. Examination, blood results and sometimes scans or bone-marrow assessments show how the disease is responding. In AML, marrow findings help distinguish persistent disease from treatment-related low counts, which may require different decisions.

Common side effects and practical management

Low blood counts and tiredness

A fall in neutrophils, a type of white blood cell, increases infection risk. Anaemia can cause fatigue, breathlessness and dizziness. Low platelets can cause bruising or bleeding. These effects may come from treatment, the disease or both. Your team may use treatment breaks, growth-factor injections, transfusions or other support. Do not adjust venetoclax yourself because of a blood-test result.

Balance gentle activity with rest and ask for help with demanding tasks. New severe exhaustion, faintness or breathlessness deserves assessment rather than being dismissed as ordinary tiredness.

Nausea, diarrhoea and constipation

Take prescribed anti-sickness treatment as directed. Small regular meals may be easier than large ones. Contact the team if nausea prevents you eating, drinking or taking your medicines. Follow your prescribed fluid target rather than a generic instruction to drink unlimited amounts.

Report diarrhoea, especially if frequent, persistent or accompanied by fever, blood, pain or reduced urine. The team can advise appropriate treatment and check for infection. Constipation may improve with a suitable diet, activity and a prescribed laxative, but severe abdominal pain or vomiting needs urgent advice.

Mouth discomfort, swelling and other symptoms

A sore mouth, appetite changes, muscle or joint aches, headache and swelling can occur, particularly with accompanying treatments. Gentle mouth care and early discussion of pain or poor intake help prevent problems escalating. Report new or increasing swelling, especially with breathlessness. Side-effect patterns vary by regimen; percentages from a combination study do not describe venetoclax alone.

Important risks that need medical assessment

Tumour lysis syndrome

TLS can develop within six to eight hours of a first dose or increase, and can occur when treatment restarts after an interruption. Severe cases can cause kidney failure, dangerous heart rhythms, seizures or death. Fatal cases have occurred after a single 20 mg dose, which is why even a small starting dose needs the agreed safeguards.

Possible warning signs include nausea or vomiting, marked weakness, unusual sleepiness, muscle cramps, an irregular heartbeat, cloudy or reduced urine, confusion or seizures. Some changes appear only in blood tests. Seek immediate advice for symptoms; do not try to treat suspected TLS by drinking extra water at home.

Serious infection

Pneumonia, bloodstream infection and other serious infections can occur. Infection can progress rapidly when neutrophils are low. Call immediately for fever at the threshold your team gives you, shaking chills, a new cough, breathlessness, painful urination or feeling suddenly very unwell. A serious infection can occur without a high temperature.

Preventive antimicrobial medicines may be prescribed, but they do not remove the need to report symptoms. Some antifungal medicines strongly interact with venetoclax, so the infection-prevention plan and tablet dose must be checked together. The team may interrupt venetoclax during a serious infection.

Adding another cancer medicine can change this risk. The current US label highlights more serious and fatal infections when obinutuzumab was added to venetoclax and acalabrutinib in a trial; it says the safety and effectiveness of that three-medicine regimen are not established there. European instructions include that combination. If it is proposed, ask the team to explain the evidence and your infection-prevention plan. Do not change an agreed regimen yourself.

Bleeding and severe blood-count changes

Contact the team promptly about unexplained bruising, persistent nosebleeds or bleeding gums. Uncontrolled bleeding, blood in vomit, black stools or a sudden severe headache need emergency assessment. Do not start aspirin or anti-inflammatory painkillers without checking whether they are suitable for your platelet count and other medicines.

Other medicines, supplements and vaccines

Venetoclax levels are affected by proteins that process or transport medicines, particularly CYP3A and P-gp. Certain antifungals, antibiotics, antiviral medicines, heart medicines and seizure treatments can cause major interactions. Starting or stopping another medicine may require a new venetoclax prescription.

Strong CYP3A inhibitors must not be combined with venetoclax during the CLL starting ramp-up. In AML, some of these combinations are used with a specialist-adjusted starting schedule. Posaconazole has specific US dose instructions that differ from the general European strong-inhibitor table. Never borrow an antifungal-related dose from another patient or calculate the reduction yourself. Moderate inhibitors also commonly require substantial dose reduction.

Avoid St John's wort and check all herbal or Ayurvedic preparations before use. Avoid grapefruit, Seville oranges and starfruit, including products containing them. Ordinary sweet oranges are different from Seville oranges, but check unfamiliar mixed juices or marmalades.

Warfarin may need closer clotting tests. Digoxin and some other medicines may require avoidance or carefully directed timing; simply separating every interacting medicine by a few hours does not solve the problem.

Do not receive live vaccines before, during or after treatment until the team confirms appropriate immune recovery. Non-live vaccines may be offered, although protection can be reduced. Discuss timing with the team rather than applying a fixed post-treatment interval.

Everyday life during treatment

Use a daily calendar or checklist to record the prescribed dose and whether you have taken it. During ramp-up, keep each week's supply clearly identified and check the dose with a caregiver if helpful. Do not remove the next week's tablets early if this creates a risk of confusion.

Plan work and travel around blood tests and access to urgent care. The first weeks often require more flexibility than later treatment. Do not drive if dizzy, very tired or unwell. Follow the team's food-hygiene and infection-prevention advice, while maintaining comfortable contact with family and friends.

Tell dentists and other clinicians about treatment and low blood counts before procedures. Ask before using over-the-counter pain medicines or drinking alcohol, particularly if liver tests are abnormal. Practical concerns about costs, transport or caregiving are worth raising early so they do not lead to unplanned missed treatment. If treatment is affecting intimacy, confidence or emotional wellbeing, ask about supportive care; you do not have to manage these concerns alone.

Fertility, contraception, pregnancy and breastfeeding

Venetoclax can harm an unborn baby. A pregnancy test is recommended before treatment for people who could become pregnant. Use effective contraception during treatment and for at least 30 days after the final dose. European instructions specify highly effective contraception and advise adding a barrier method if using hormonal contraception. Partner medicines may require a longer period, so obtain a plan for the whole regimen.

Contact the team promptly if pregnancy occurs or is suspected. Do not assume an absent menstrual period means pregnancy is impossible. Venetoclax may affect male fertility; discuss sperm storage before treatment if future biological parenthood matters. The labels do not give one universal male contraception interval for venetoclax, but accompanying medicines can impose their own requirements.

Do not breastfeed during treatment. The US label also specifies at least one week after the last dose. European information does not specify a fixed post-treatment restart interval. Ask when breastfeeding can safely resume after the complete regimen rather than treating one week as a universal clearance.

After a pause or when treatment finishes

Never restart leftover tablets after a treatment break without speaking to the team. In CLL, interruptions longer than one week during ramp-up or longer than two weeks afterwards require reassessment of TLS risk; a lower restart dose or repeated dose steps may be necessary. Shorter interruptions can also need advice, particularly if illness, dehydration or interacting medicines are involved.

A planned end date varies with the accompanying treatment and response. Finishing a fixed course, shortening an AML cycle, temporarily holding treatment and permanently stopping are different decisions. Ask which applies and what monitoring continues. Keep infection and reproductive precautions until the team confirms the relevant recovery periods.

Frequently asked questions